Sagar Lonial, MD, FACP, details additional agents of interest outside CAR T-cell therapies in multiple myeloma including the recently approved agents elranatamab and talquetamab.
Sagar Lonial, MD, FACP, discusses the final overall survival analysis of the phase 3 IKEMA trial of isatuximab when combined with carfilzomib and dexamethasone in patients with relapsed multiple myeloma, highlighting the progression-free survival and OS outcomes.